Share this video  

ESMO 2017 | Grant McArthur on the 3 positive melanoma trials presented at the ESMO 2017 Congress

Grant McArthur • 11 Sep 2017
ESMO 2017
Melanoma Dabrafenib Nivolumab Trametinib
BRIM8 CheckMate 23 COMBI-AD

We spoke to Grant McArthur during the ESMO 2017 Congress in Madrid, Spain to get his take on the exciting new data presented in melanoma during the meeting. As well as commenting on the data of the COMBI-AD, BRIM8 and CheckMate23 trials, he also emphasizes how well tolerated some of these medicines have been.

More from Grant McArthur

2:49
The developments of genetic testing and personalized cancer vaccines for patients with skin cancer
Grant McArthur • 31 Aug 2016
2:29
Overcoming resistance to immunotherapy
Grant McArthur • 10 Sep 2017
3:34
Recent developments in melanoma with brain metastases
Grant McArthur • 1 Jun 2018
3:08
OS rates and prognostic categories for BRAF-mutated melanoma when treated with combination therapy
Grant McArthur • 3 Jun 2016

Related Videos

4:11
Limiting duration of treatment with checkpoint inhibitors: the data
Jeffrey Weber • 18 Jan 2019
6:25
Combination targeted adjuvant therapy doubles relapse-free survival in stage III melanoma
Axel Hauschild • 11 Sep 2017
1:37
The PLATforM trial: clinical updates on spartalizumab antibody treatment
Jeffrey Weber • 4 Jan 2019
2:41
Landmark clinical trials for melanoma treatment
Christian Blank • 20 Sep 2017
The content of VJOncology is intended for healthcare professionals